TABLE 3.

Parameters linked to HHV-8 DNA detection

Characteristic	No. (%) of women			P valuea	Antibody GMTc		Antibody titer during the indicated trimester:
							Women with PCR-positive samples			Women with PCR-negative samples
	Total	With PCR-positive samples	With PCR-negative samples		Women with PCR-positive samples	Women with PCR-negative samples	I	II	III	I	II	III
Age
>30 yr	8 (53)	6 (75)	2 (25)	0.04
<30 yr	7 (47)	1 (14)	6 (86)
Antiretroviral therapy
Schedule
Whole pregnancy	7 (53)	1 (14)	6 (86)	0.04
From the second trimester or untreated	8 (47)	6 (75)	2 (25)
Type
With protease inhibitor	5 (33)		5 (100)	0.02
Without protease inhibitor or untreated	10 (67)	7 (70)	3 (30)
HHV-8 antibody detectionb
ORF65	7 (40)	6 (83)	1 (17)	0.01	252 (137-464)d	50e	348	230	200	NDf	ND	ND
LANA	15 (100)	7 (47)	8 (53)		981 (477-2,018)g	194 (113-333)	1,212	1,007	800	297	200	135
At least one antigen	15 (100)	7 (47)	8 (53)

^aAll P values were estimated by Fisher's exact test; antibody titers were compared by means of unpaired t test after log₁₀transformation to achieve normality.

^bHHV-8 seropositivity is reported as the presence of antibodies to a structural ORF65-encoded protein, a LANA, or to at least one of these two antigens.

^cValues in parentheses are the 95% CI.

^dP = 0.001 for the difference between the two groups.

^eAntibody titer for one woman. Statistical analysis was performed by assigning an arbitrary antibody titer of 20 to plasma samples found to be negative.

^fND, not done.

^gP = 0.069 for the difference between the two groups.